$FHTX
Foghorn Therapeutics Inc.

2024 Q4 Form 10-Q Financial Statement

#000162828024045006 Filed on November 04, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $7.808M
YoY Change -55.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.971M
YoY Change -16.11%
% of Gross Profit
Research & Development $24.69M
YoY Change -5.95%
% of Gross Profit
Depreciation & Amortization $700.0K
YoY Change -22.22%
% of Gross Profit
Operating Expenses $31.66M
YoY Change -8.39%
Operating Profit -$23.85M
YoY Change 39.64%
Interest Expense $3.495M
YoY Change 27.09%
% of Operating Profit
Other Income/Expense, Net $4.730M
YoY Change 36.15%
Pretax Income -$19.12M
YoY Change 40.53%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$19.12M
YoY Change 33.3%
Net Earnings / Revenue -244.9%
Basic Earnings Per Share -$0.31
Diluted Earnings Per Share -$0.31
COMMON SHARES
Basic Shares Outstanding 55.59M shares 55.33M shares
Diluted Shares Outstanding 62.60M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $267.4M
YoY Change 2.89%
Cash & Equivalents $57.68M
Short-Term Investments $209.7M
Other Short-Term Assets $3.837M
YoY Change -31.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $271.2M
YoY Change 2.18%
LONG-TERM ASSETS
Property, Plant & Equipment $34.58M
YoY Change -23.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $848.0K
YoY Change -24.89%
Total Long-Term Assets $37.14M
YoY Change -22.6%
TOTAL ASSETS
Total Short-Term Assets $271.2M
Total Long-Term Assets $37.14M
Total Assets $308.4M
YoY Change -1.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.451M
YoY Change -46.88%
Accrued Expenses $11.22M
YoY Change 27.5%
Deferred Revenue $33.38M
YoY Change 17.78%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $56.82M
YoY Change 9.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $279.8M
YoY Change
Total Long-Term Liabilities $279.8M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $56.82M
Total Long-Term Liabilities $279.8M
Total Liabilities $336.7M
YoY Change -9.21%
SHAREHOLDERS EQUITY
Retained Earnings -$538.7M
YoY Change 20.38%
Common Stock $6.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$28.29M
YoY Change
Total Liabilities & Shareholders Equity $308.4M
YoY Change -1.61%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$19.12M
YoY Change 33.3%
Depreciation, Depletion And Amortization $700.0K
YoY Change -22.22%
Cash From Operating Activities -$21.01M
YoY Change -22.78%
INVESTING ACTIVITIES
Capital Expenditures $309.0K
YoY Change 209.0%
Acquisitions
YoY Change
Other Investing Activities -$61.01M
YoY Change -258.05%
Cash From Investing Activities -$61.32M
YoY Change -259.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.051M
YoY Change -24.93%
NET CHANGE
Cash From Operating Activities -21.01M
Cash From Investing Activities -61.32M
Cash From Financing Activities 1.051M
Net Change In Cash -81.27M
YoY Change -739.91%
FREE CASH FLOW
Cash From Operating Activities -$21.01M
Capital Expenditures $309.0K
Free Cash Flow -$21.31M
YoY Change -21.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001822462
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Local Phone Number
LocalPhoneNumber
586-3100
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
FHTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80336000 usd
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
209719000 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
153721000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29956000 usd
CY2024Q3 us-gaap Assets
Assets
308372000 usd
CY2023Q4 us-gaap Assets
Assets
285916000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3451000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6260000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11219000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9108000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8770000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8518000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
249535000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
268115000 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42282040 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42282040 shares
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7808000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17478000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24689000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26251000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6971000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8308000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62602848 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62602848 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30488000 usd
dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1708000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59386000 usd
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.foghorntx.com/20240930#CollaborationRevenueMember
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.foghorntx.com/20240930#CollaborationRevenueMember
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity Registrant Name
EntityRegistrantName
Foghorn Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5271393
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Technology Square, Ste 700
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-471564000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-28287000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
308372000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
33384000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
34550000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
56824000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
58436000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30300000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36555000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
336659000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
363106000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55593131 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55593131 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
510028000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
395196000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
360000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-826000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-538681000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-77190000 usd
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.foghorntx.com/20240930#CollaborationRevenueMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.foghorntx.com/20240930#CollaborationRevenueMember
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55593131 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57678000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3837000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6124000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
271234000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
240181000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
10513000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
12956000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1708000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
848000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1115000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24069000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
285916000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19746000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28386000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74020000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85484000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22006000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25350000 usd
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2398000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
31660000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
34559000 usd
us-gaap Operating Expenses
OperatingExpenses
98424000 usd
us-gaap Operating Expenses
OperatingExpenses
110834000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17081000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-78678000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-82448000 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
3495000 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
2753000 usd
us-gaap Interest Income Other
InterestIncomeOther
8804000 usd
us-gaap Interest Income Other
InterestIncomeOther
8215000 usd
CY2024Q3 fhtx Interest Income And Other Income Expense
InterestIncomeAndOtherIncomeExpense
1235000 usd
CY2023Q3 fhtx Interest Income And Other Income Expense
InterestIncomeAndOtherIncomeExpense
721000 usd
fhtx Interest Income And Other Income Expense
InterestIncomeAndOtherIncomeExpense
2757000 usd
fhtx Interest Income And Other Income Expense
InterestIncomeAndOtherIncomeExpense
2153000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4730000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3474000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11561000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10368000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19122000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13607000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67117000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72080000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
738000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2240000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19122000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14345000 usd
us-gaap Net Income Loss
NetIncomeLoss
-67117000 usd
us-gaap Net Income Loss
NetIncomeLoss
-74320000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41888314 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14345000 usd
us-gaap Net Income Loss
NetIncomeLoss
-67117000 usd
us-gaap Net Income Loss
NetIncomeLoss
-74320000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
698000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
826000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1186000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2093000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
698000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
826000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1186000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2093000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18424000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13519000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65931000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72227000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-77190000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1167000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3224000 usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
329000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-25016000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-97486000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
102816000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000 shares
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23852000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42025938 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42025938 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52241942 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52241942 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41888314 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19122000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3168000 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
159000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-22979000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-14322000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1441000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3018000 usd
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
698000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19122000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-28287000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
112000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
102000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4572000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1116000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-24586000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
102000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4470000 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
151000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29487000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-49350000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1387000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4094000 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
826000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14345000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-57388000 usd
us-gaap Net Income Loss
NetIncomeLoss
-67117000 usd
us-gaap Net Income Loss
NetIncomeLoss
-74320000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9410000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13135000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2359000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2599000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2398000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
fhtx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
4254000 usd
fhtx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
3815000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3044000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2156000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2554000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1297000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2809000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1082000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1857000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2129000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6003000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5505000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-19746000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28386000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75887000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90565000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
427000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1187000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
221821000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67061000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
170053000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
175312000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52195000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
107065000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
103401000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
585000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2608000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1592000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105424000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1592000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22658000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18092000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82044000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53922000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72014000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
813000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2686000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
289000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
58000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57678000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70306000 usd
CY2024Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1708000 usd
CY2023Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1708000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59386000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72014000 usd
us-gaap Net Income Loss
NetIncomeLoss
-67100000 usd
us-gaap Net Income Loss
NetIncomeLoss
-74300000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-538700000 usd
CY2023Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
209359000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
385000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
209719000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
154547000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
844000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
153721000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
24835000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
24973000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
14322000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
12017000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
10513000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
12956000 usd
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
900000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2400000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2600000 usd
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
800000 usd
CY2024Q3 fhtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
6602000 usd
CY2023Q4 fhtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3610000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3771000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4347000 usd
CY2024Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 usd
CY2023Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
674000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
633000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
441000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
213000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
36000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11219000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9108000 usd
CY2024Q3 fhtx Common Stock Voting Rights Votes
CommonStockVotingRightsVotes
1 vote
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
7220794 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2024Q3 fhtx Class Of Warrant Or Right Pre Funded Warrants Exercised
ClassOfWarrantOrRightPreFundedWarrantsExercised
0 shares
fhtx Class Of Warrant Or Right Pre Funded Warrants Exercised
ClassOfWarrantOrRightPreFundedWarrantsExercised
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9035007 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9551175 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1566120 shares
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3018000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4094000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9410000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13135000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
18500000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
fhtx-20240930_htm.xml Edgar Link completed
0001628280-24-045006-index-headers.html Edgar Link pending
0001628280-24-045006-index.html Edgar Link pending
0001628280-24-045006.txt Edgar Link pending
0001628280-24-045006-xbrl.zip Edgar Link pending
ex101foghornemploymentagre.htm Edgar Link pending
fhtx-20240930.htm Edgar Link pending
fhtx-20240930.xsd Edgar Link pending
fhtx-20240930xex311.htm Edgar Link pending
fhtx-20240930xex312.htm Edgar Link pending
fhtx-20240930xex321.htm Edgar Link pending
fhtx-20240930xex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
fhtx-20240930_def.xml Edgar Link unprocessable
fhtx-20240930_lab.xml Edgar Link unprocessable
fhtx-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fhtx-20240930_cal.xml Edgar Link unprocessable